In the Spotlight...
Molecular heterogeneity and clonal origin of CCR8+ effector regulatory T cells in human cancer
Immune checkpoint blockade facilitates primary tumor rejection in a cDC1-independent manner without immunological memory acquisition
Neutralizing the IL-12/IL-23 p40 subunit prevents immune checkpoint blockade toxicity without compromising antitumor efficacy
Antigen presentation requirements for effective cDC1-based cancer immunotherapy
Previous Digests
Aire-ing out a tumor’s dirty laundry: manipulating tumoral AIRE to boost antitumor immunity
September 2, 2026
The autoimmune regulator (AIRE) transcription factor in medullary thymic epithelial cells (mTECs) is essential for the negative selection of autoreactive T cells in the thymus by inducing expression of peripheral tissue-specific antigens. Chen, Pulido, et al. hypothesized that AIRE...
Fun in the sun: how melanocytes avoid immune clearance, despite UV damage
August 19, 2026
Melanocytes in human skin are regularly exposed to ultraviolet radiation (UVR) from the sun, and can accumulate substantial DNA damage without being eliminated by the immune system. In recent work published in Immunity, Lo et al. investigated how these...
Activated DCs go beyond priming to sustain tumoral T cell responses
August 12, 2026
A subset of cDCs within tumors expresses T cell-stimulating and immune-regulatory molecules. The exact role of these activated DCs (actDCs) in antitumor immunity remains largely unknown, and given their scarcity, they are a challenge to study. Koufaki et al...
Watch ACIR in action
In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.
Watch the 3-minute video explaining ACIR's mission and goal:
In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.
Watch the 6-minute segment on the story behind your favorite digest here:
About ACIR
ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.
Ute Burkhardt
Ed Fritsch
Lauren Hitchings
Gaëlle Llambi
Maartje Wouters
Alex Najibi
Katherine J. Turner
Stan Wolf
Paula Hochman
Shishir Pant
Nathan Suek
Morgan Janes
TESTIMONIALS
I'm a big fan of ACIR. I enjoy their weekly newsletters with clear, concise, and insightful summaries, complemented by excellent images. I've even used the images in some of my presentations to explain complex cancer immunotherapy findings. In our rapidly evolving field, their reliable and well-curated updates are invaluable.
Richard W. Vague Professor in Immunotherapy; Professor of PL&M; Director, Center for Cellular Immunotherapies; Director, Parker Institute for Cancer Immunotherapy; University of Pennsylvania Perelman School of Medicine. (Supporter since 2025).
Current Sponsors
